Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Position Boosted by Northwestern Mutual Investment Management Company LLC

Northwestern Mutual Investment Management Company LLC increased its holdings in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 34.0% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,158 shares of the biopharmaceutical company’s stock after buying an additional 1,056 shares during the quarter. Northwestern Mutual Investment Management Company LLC’s holdings in Regeneron Pharmaceuticals were worth $2,030,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of the stock. Parkside Financial Bank & Trust grew its holdings in Regeneron Pharmaceuticals by 44.2% in the 1st quarter. Parkside Financial Bank & Trust now owns 62 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 19 shares in the last quarter. Icon Wealth Partners LLC grew its holdings in Regeneron Pharmaceuticals by 3.8% in the 1st quarter. Icon Wealth Partners LLC now owns 659 shares of the biopharmaceutical company’s stock worth $322,000 after buying an additional 24 shares in the last quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC grew its holdings in Regeneron Pharmaceuticals by 1.4% in the 1st quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 2,149 shares of the biopharmaceutical company’s stock worth $1,048,000 after buying an additional 29 shares in the last quarter. Investment House LLC grew its holdings in Regeneron Pharmaceuticals by 2.5% in the 1st quarter. Investment House LLC now owns 1,210 shares of the biopharmaceutical company’s stock worth $591,000 after buying an additional 30 shares in the last quarter. Finally, CX Institutional grew its holdings in Regeneron Pharmaceuticals by 144.0% in the 1st quarter. CX Institutional now owns 61 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 36 shares in the last quarter. 66.58% of the stock is owned by institutional investors and hedge funds.

REGN has been the subject of a number of research analyst reports. Wells Fargo & Co upped their target price on Regeneron Pharmaceuticals from $370.00 to $435.00 and gave the stock an “equal weight” rating in a research report on Monday, April 6th. Citigroup downgraded Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and upped their target price for the stock from $540.00 to $575.00 in a research report on Tuesday, April 28th. Jefferies Financial Group upgraded Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and upped their target price for the stock from $355.00 to $492.00 in a research report on Tuesday, February 25th. Barclays initiated coverage on Regeneron Pharmaceuticals in a research report on Thursday, February 27th. They issued an “overweight” rating and a $530.00 target price for the company. Finally, BidaskClub upgraded Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, May 7th. Fourteen analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $515.26.

NASDAQ REGN opened at $569.91 on Friday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.49 and a current ratio of 4.21. The firm has a 50-day simple moving average of $541.71 and a 200 day simple moving average of $427.59. Regeneron Pharmaceuticals Inc has a twelve month low of $271.37 and a twelve month high of $583.54. The stock has a market cap of $61.72 billion, a PE ratio of 28.64, a PEG ratio of 1.23 and a beta of 0.53.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Tuesday, May 5th. The biopharmaceutical company reported $6.60 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $6.13 by $0.47. Regeneron Pharmaceuticals had a net margin of 28.56% and a return on equity of 24.94%. The business had revenue of $1.83 billion during the quarter, compared to analysts’ expectations of $1.81 billion. During the same quarter last year, the company earned $4.45 earnings per share. The firm’s revenue was up 6.8% on a year-over-year basis. Research analysts forecast that Regeneron Pharmaceuticals Inc will post 23.84 earnings per share for the current fiscal year.

In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 100 shares of the firm’s stock in a transaction dated Monday, March 30th. The shares were sold at an average price of $466.69, for a total transaction of $46,669.00. Following the completion of the transaction, the director now owns 29,141 shares in the company, valued at $13,599,813.29. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director George L. Sing sold 850 shares of the firm’s stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $575.00, for a total transaction of $488,750.00. Following the transaction, the director now owns 120,415 shares of the company’s stock, valued at approximately $69,238,625. The disclosure for this sale can be found here. In the last quarter, insiders sold 196,397 shares of company stock valued at $109,206,506. 11.84% of the stock is owned by corporate insiders.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

Featured Story: Systematic Risk

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.